NEW YORK–(BUSINESS WIRE)–#classaction–The law firm of Kirby
McInerney LLP is investigating potential claims against Trevena Inc.
(“Trevena” or the “Company”) (NASDAQ:TRVN). This investigation concerns
whether Trevena has violated federal securities laws and/or engaged in
other unlawful business practices.
On May 2, 2016, Trevena announced that it had “reached general
agreement” with the FDA on key elements of its Phase 3 program for
oliceridine (TRV130) and was “very pleased” with the outcome of its
discussions with the FDA.
However, on October 9, 2018, minutes from the FDA’s April 28, 2016
meeting with Trevena were released and showed that the FDA: “did not
agree with the proposed dosing in the Phase 3 studies”; “did not agree
with the proposed primary endpoint”; and “did not agree with the
proposed non-inferiority (NI) margin for comparing morphine to
On this news, Trevena shares fell $1.91, or over 64%, to close at $1.07
on October 9, 2018.
If you purchased or otherwise acquired Trevena securities, have
information, or would like to learn more about these claims, please
W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at email@example.com,
or by filling out this
contact form, to discuss your rights or interests with respect to
these matters without any cost to you.
McInerney LLP is a New York-based plaintiffs’ law firm concentrating
in securities, antitrust, and whistleblower litigation. The firm’s
efforts on behalf of shareholders in securities litigation have resulted
in recoveries totaling billions of dollars. Additional information about
the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.